Is NCT06603246 recruiting in Pittsburgh, PA?

Yes, NCT06603246 is currently recruiting participants at its Pittsburgh, PA location. This muco-obstructive disease clinical trial is actively enrolling qualified participants.

How do I join the muco-obstructive disease clinical trial in Pittsburgh?

To join this clinical trial in Pittsburgh, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Pittsburgh clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Muco-Obstructive Disease Clinical Trial in Pittsburgh, PA

Who Can Participate

Inclusion Criteria

Percent predicted FEV1 ≥ 40% by spirometry during screening

Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment

On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and willingness to remain on the stable treatment regimen through completion of study

Stable disease for ≥ 28 days prior to screening and through to initiation of study treatment Additional Inclusion Criteria for Participants in Part B

Chronic sputum production of ≥1 teaspoon per day as reported in the sputum volume item

Ability to produce a sputum sample that is suitable for central laboratory determination of mucus percent solids and sialic acid concentration exploratory biomarker research, and biomarker assay development

Availability of a representative blood sample for exploratory biomarker research and biomarker assay development Additional Inclusion Criteria for Participants With Non-cystic Fibrosis Bronchiectasis (NCFB) (Cohort 1, Cohort 2, and Cohort 3): \- Diagnosis of bronchiectasis on the basis of prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung as assessed by the investigator Additional Inclusion Criteria for Participants With Chronic Obstructive Pulmonary Disease (COPD) (Cohort 1, Cohort 2, and Cohort 4):

COPD defined as post-bronchodilator FEV1/FVC ratio of \<0.7

Chronic bronchitis, with a definition including chronic cough and excessive sputum production for more than 3 months per year for at least 2 years prior to screening

Former smoker with a minimum of 10 pack-year history (e.g., 20 cigarettes/day for 10 years) or non-smoker with at least one documented COPD risk factor

Exclusion Criteria

Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the timeframe in which contraception is required

Known significant bronchodilator response of \>10% predicted change in FEV1 or FVC, in the investigator's judgment

Use of any prohibited medications

Acute respiratory infection within 28 days of screening

Significant hemoptysis greater than 60 milliliter (mL) within 3 months prior to screening

Known immunodeficiency that, in the investigator's judgment, is clinically significant and places the individual at a substantially elevated risk for opportunistic infections.

Known substance abuse, in the investigator's judgment, within 12 months prior to screening

Poor peripheral venous access

Receipt of blood products within 120 days prior to screening

Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results

History of thoracic or metastatic malignancy within 5 years prior to screening

Known history of a clinically significant abnormal electrocardiogram (ECG), or presence of an abnormal ECG that is deemed clinically significant by the investigator

QT interval corrected through use of Fridericia's formula (QTcF) \>450 milliseconds (ms) for males or \>470 ms for females Additional Exclusion Criteria for Participants in Part B -More than 2 chest CTs or other procedures known to expose the lungs to greater than 100 millisievert (mSv) within 12 months prior to screening Additional Exclusion Criteria for Participants With NCFB (Cohort 1, Cohort 2, and Cohort 3)

Bronchiectasis primarily due to cystic fibrosis, primary ciliary dyskinesia, non-tuberculous mycobacterial infection, chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD), in the investigator's judgment

Diagnosis of asthma, that in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary asthma with incidental bronchiectasis findings)

NCFB exacerbation within 28 days prior to screening or that has not returned to baseline

Current smoker: Current smoking is defined as any use of inhaled tobacco products or inhaled marijuana within 3 months prior to screening, through use of cigarettes, cigars, electronic cigarettes, vaporizing devices, or pipes. Additional Exclusion Criteria for Participants with NCFB in Cohort 3 \- Diagnosis of COPD that, in the investigator's judgment, is the primary driver of the individual's respiratory disease (e.g., primary COPD with incidental bronchiectasis findings) Additional Exclusion Criteria for Participants With COPD (Cohort 1, Cohort 2, and Cohort 4):

COPD exacerbation within 28 days prior to screening or that has not returned to baseline

Asthma/COPD overlap syndrome

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT06603246) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Muco-Obstructive Disease Treatment Options in Pittsburgh, PA

If you're searching for muco-obstructive disease treatment options in Pittsburgh, PA, this clinical trial (NCT06603246) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced muco-obstructive disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all muco-obstructive disease clinical trials near you to find additional studies recruiting in your area.

Muco-Obstructive Disease Clinical Trial in Pittsburgh, PA

Expert Care in Pittsburgh

IRB Approved

No-Cost Care

Apply for This Pittsburgh Location

Why Participate?

Simple Process

About This Muco-Obstructive Disease Study in Pittsburgh